Prevention and treatment of relapse after stem cell transplantation by cellular therapies

Fred Falkenburg, Eliana Ruggiero, Chaira Bonini, David Porter, Jeff Miller, Floran Malard, Mohamad Mohty, Nicolaus Kröger, Hans Jochem Kolb

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Despite recent advances in reducing therapy-related mortality after allogeneic stem cell transplantation (alloSCT) relapse remains the major cause of treatment failure and little progress has been achieved in the last decades. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg/Germany in November 2016 international experts presented and discussed recent developments in the field. Here, the potential of cellular therapies including unspecific and specific T cells, genetically modified T cells, CAR-T cells, NK-cells, and second allografting in prevention and treatment of relapse after alloSCT are summarized.

Original languageEnglish (US)
Pages (from-to)26-34
Number of pages9
JournalBone marrow transplantation
Issue number1
StatePublished - Jan 1 2019

Bibliographical note

Publisher Copyright:
© 2018, Macmillan Publishers Limited, part of Springer Nature.


Dive into the research topics of 'Prevention and treatment of relapse after stem cell transplantation by cellular therapies'. Together they form a unique fingerprint.

Cite this